Table 2.

Comparison of the detection rates of actionable mutations in early-stage lung adenocarcinoma in primary tumors and loco-regional lymph-node metastases.

	Primary Tumor (n = 514)	Loco-Regional Lymph Node (n = 44)	p-Value
	N (%)	N (%)
EGFR	68 (13.2%)	4 (9.1%)	0.6381
KRAS p.G12C	87 (16.9%)	10 (22.7%)	0.4429
BRAF p.V600E	10 (1.9%)	1 (2.3%)	0.5983
ERBB2	5 (1%)	0 (0%)	1
ALK	7 (1.4%)	0 (0%)	1
ROS-1	1 (0.2%)	0 (0%)	1
RET	5 (1%)	1 (2.3%)	0.3905
MET Exon 14 skipping	13 (2.5%)	3 (6.8%)	0.1243
No alterations	67 (13%)	7 (15.9%)	0.7581